A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Enrolling By Invitation
18-99 years
All
Phase
1
10 participants needed
1 Location
Brief description of study
This study is being done to determine what effects the therapy venetoclax has on acute lymphoblastic leukemia (ALL).This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed ALL.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: B Acute Lymphoblastic LeukemiaLymphoblasts 5 Percent or More of Bone Marrow Nucleated CellsRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaT Acute Lymphoblastic Leukemia
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 830092
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
